OPKO Health (NASDAQ:OPK) Stock Crosses Above 50 Day Moving Average of $1.09

Shares of OPKO Health, Inc. (NASDAQ:OPK) passed above its fifty day moving average during trading on Friday . The stock has a fifty day moving average of $1.09 and traded as high as $1.26. OPKO Health shares last traded at $1.26, with a volume of 1,947,276 shares trading hands.

Analysts Set New Price Targets

Several brokerages have recently issued reports on OPK. Piper Sandler reissued an “overweight” rating and issued a $5.00 price objective on shares of OPKO Health in a report on Monday, April 1st. HC Wainwright reaffirmed a “buy” rating and issued a $3.00 price target on shares of OPKO Health in a report on Wednesday, April 3rd. StockNews.com cut OPKO Health from a “hold” rating to a “sell” rating in a report on Friday, March 1st. Finally, Barrington Research reaffirmed an “outperform” rating and issued a $1.50 price target on shares of OPKO Health in a report on Monday, April 1st.

OPKO Health Stock Up 3.3 %

The business has a fifty day moving average of $1.09 and a two-hundred day moving average of $1.23. The company has a market cap of $878.21 million, a price-to-earnings ratio of -5.04 and a beta of 1.82. The company has a current ratio of 1.55, a quick ratio of 1.22 and a debt-to-equity ratio of 0.15.

OPKO Health (NASDAQ:OPK) last announced its earnings results on Tuesday, February 27th. The biotechnology company reported ($0.09) EPS for the quarter, meeting analysts’ consensus estimates of ($0.09). OPKO Health had a negative return on equity of 12.69% and a negative net margin of 21.76%. The business had revenue of $181.90 million during the quarter, compared to analysts’ expectations of $177.53 million. During the same quarter in the prior year, the firm earned ($0.11) earnings per share. The business’s revenue was down 1.9% compared to the same quarter last year. As a group, equities analysts anticipate that OPKO Health, Inc. will post -0.33 EPS for the current fiscal year.

Insider Buying and Selling at OPKO Health

In other news, CEO Phillip Md Et Al Frost bought 500,000 shares of OPKO Health stock in a transaction on Monday, March 18th. The stock was acquired at an average price of $0.87 per share, with a total value of $435,000.00. Following the completion of the acquisition, the chief executive officer now directly owns 210,968,225 shares of the company’s stock, valued at $183,542,355.75. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In related news, Director Richard M. Krasno purchased 30,000 shares of the company’s stock in a transaction dated Monday, January 29th. The stock was acquired at an average cost of $0.99 per share, for a total transaction of $29,700.00. Following the completion of the transaction, the director now directly owns 103,333 shares of the company’s stock, valued at $102,299.67. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CEO Phillip Md Et Al Frost purchased 500,000 shares of the company’s stock in a transaction dated Monday, March 18th. The stock was bought at an average price of $0.87 per share, with a total value of $435,000.00. Following the completion of the transaction, the chief executive officer now directly owns 210,968,225 shares of the company’s stock, valued at $183,542,355.75. The disclosure for this purchase can be found here. Insiders bought 4,630,000 shares of company stock valued at $4,422,700 over the last quarter. 47.26% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in OPK. IPG Investment Advisors LLC acquired a new stake in shares of OPKO Health in the fourth quarter valued at $30,000. River Wealth Advisors LLC acquired a new stake in shares of OPKO Health in the third quarter valued at $38,000. SlateStone Wealth LLC acquired a new stake in shares of OPKO Health in the first quarter valued at $31,000. Northstar Group Inc. acquired a new stake in shares of OPKO Health in the fourth quarter valued at $42,000. Finally, EP Wealth Advisors LLC raised its stake in shares of OPKO Health by 140.3% in the third quarter. EP Wealth Advisors LLC now owns 30,900 shares of the biotechnology company’s stock valued at $49,000 after acquiring an additional 18,041 shares in the last quarter. 64.63% of the stock is currently owned by institutional investors and hedge funds.

About OPKO Health

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.